YS Biopharma Co., Ltd.
Stock Forecast, Prediction & Price Target

	Passed			Analyst forecast
Metric	3/31/2021	3/31/2022	3/31/2023	3/31/2026	3/31/2027
Revenue % change YoY	$257.01M N/A	$502.94M 95.68%	$687.20M 36.63%	Avg: $1.38B Low: $1.38B High: $1.38B avg. 101.81%	Avg: $1.80B Low: $1.80B High: $1.80B avg. 30.00%
Net Income % change YoY	$-191.82M N/A	$-106.00M 44.73%	$-145.47M -37.23%	Avg: $118.44M Low: $93.98M High: $93.98M avg. 181.41%	Avg: $431.60M Low: $341.52M High: $341.52M avg. 264.41%
EBITDA % change YoY	$-116.77M N/A	$-67.19M 42.45%	$-76.82M -14.32%	Avg: $-323.49M Low: $-323.49M High: $-323.49M avg. -321.09%	Avg: $-420.56M Low: $-420.56M High: $-420.56M avg. -30.00%
EPS % change YoY	-$2.08 N/A	-$1.15 44.71%	-$1.56 -35.65%	Avg: $1.01 Low: $1.01 High: $1.01 avg. 164.74%	Avg: $3.67 Low: $3.67 High: $3.67 avg. 263.36%
Operating Expenses % change YoY	$319.67M N/A	$481.82M 50.72%	$647.15M 34.31%	Avg: $849.67M Low: $849.67M High: $849.67M avg. 31.29%	Avg: $1.10B Low: $1.10B High: $1.10B avg. 30.00%

FAQ

Wall Street analysts estimate the annual average earnings growth rate of 222.91% in 2026-2027.

We have gathered data from 1 analysts. Their low estimate is 93.98M, average is 118.44M and high is 93.98M.

Wall Street analysts forecast annual average revenue growth of 65.91% in 2026-2027.

We have gathered data from 2 analysts. Their low revenue estimate is $1.38B, average is $1.38B and high is $1.38B.

Wall Street analysts forecast annual average earnings growth of 214.05% in 2026-2027.

We have gathered data from 1 analysts. Their low earnings per share estimate is $1.01, average is $1.01 and high is $1.01.